Effect of Brahmi Vati and Sarpagandha Ghana Vati in Management of Essential Hypertension - A Randomized, Double Blind, Clinical Study

Overview

Journal J Ayurveda Integr Med

Publisher Elsevier

Date 2017 Dec 16

PMID 29242090

Citations 3

Authors

Dhanpat Mishra

Basavaraj R Tubaki

Affiliations

Soon will be listed here.

Abstract

Background: Essential hypertension (EHTN) is emerging as one of the most prevalent disorder with high rate of complications, morbidity and mortality. Brahmi vati, an Ayurvedic medicine is explored for its efficacy in the management of EHTN.

Objective: To evaluate the efficacy of Brahmi vati and sarpagandha Ghana vati in the management of EHTN.

Methods: Total 68 patients meeting the JNC 7 criteria of EHTN of age group 20 to 60 years of either sex participated in the study. They were randomly divided into two groups, group A received capsule Brahmi vati 500 mg and group B capsule Sarpagandha Ghana vati 500 mg respectively twice a day for 30 days. Assessments were done through various variables like systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), lipid profiles, Hamilton anxiety rating scale, 2 weeks sleep diary, serum creatinine, hemoglobin, total leukocyte count and erythrocyte sedimentation rate. Follow up visit was on every 15th day.

Results: Study showed that both Brahmi vati and Sarpagandha Ghanavati produced improvement in most of the variables and were comparable. Improvements were seen in various variables like SBP, DBP, MAP, Hamilton anxiety rating scale, subjective sleep profiles and total cholesterol. However Brahmi vati showed increase in weight and Body Mass Index (BMI). SarpagandhaGhanavati produced reduction in total cholesterol and LDL. Both groups showed good safety profile evaluated through the assessment of serum creatinine levels.

Conclusion: Clinical efficacy of Sarpagandha Ghana vati and Brahmi vati on EHTN showed that both were effective, safe and comparable.

Citing Articles

Efficacy and safety of ayurvedic intervention (Sarpgandha Mishran) vs amlodipine for Stage-I primary hypertension- study protocol for a prospective Double-Dummy, Double-Blind, placebo-controlled Randomized Clinical Trial.

Yadav B, Rao B, Narang R, Jameela S, Khanduri S, Sharma S BMC Complement Med Ther. 2025; 25(1):88.

PMID: 40025470 PMC: 11871589. DOI: 10.1186/s12906-025-04802-4.

Efficacy of Brahmi vati and Aswagandharista in major depressive disorder: A randomized controlled trial.

Sarhyal A, Chate S, Tubaki B, Thakur R J Ayurveda Integr Med. 2024; 15(6):101022.

PMID: 39631219 PMC: 11663963. DOI: 10.1016/j.jaim.2024.101022.

Efficacy of ayurveda medications, Brahmi vati and Saraswatarista, in generalized anxiety disorder- a randomized controlled trial.

Gonugade V, Chate S, Tubaki B, Thakur R J Ayurveda Integr Med. 2024; 15(6):101033.

PMID: 39626587 PMC: 11652770. DOI: 10.1016/j.jaim.2024.101033.

Role of Vacha ( Linn.) in Neurological and Metabolic Disorders: Evidence from Ethnopharmacology, Phytochemistry, Pharmacology and Clinical Study.

Sharma V, Sharma R, Gautam D, Kuca K, Nepovimova E, Martins N J Clin Med. 2020; 9(4).

PMID: 32325895 PMC: 7230970. DOI: 10.3390/jcm9041176.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Staessen J, Thijs L, Fagard R, OBrien E, Clement D, de Leeuw P . Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999; 282(6):539-46. DOI: 10.1001/jama.282.6.539. View

Zubrzycki M, Liebold A, Janecka A, Zubrzycka M . A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol. 2014; 65(2):171-81. View

Franklin S, Gustin 4th W, Wong N, Larson M, Weber M, Kannel W . Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96(1):308-15. DOI: 10.1161/01.cir.96.1.308. View

Ried K, Frank O, Stocks N, Fakler P, Sullivan T . Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2008; 8:13. PMC: 2442048. DOI: 10.1186/1471-2261-8-13. View

Dubey M, Srimal R, Nityanand S, Dhawan B . Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol. 1981; 3(1):1-13. DOI: 10.1016/0378-8741(81)90010-6. View

Lim S, Vos T, Flaxman A, Danaei G, Shibuya K, Adair-Rohani H . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2224-60. PMC: 4156511. DOI: 10.1016/S0140-6736(12)61766-8. View

Arora R, MADAN B . Antiarrhythmics. III. Antiarrhythmic activity of Nardostachys jatamansi (an Indian indigenous drug). Indian J Med Res. 1956; 44(2):259-69. View

. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol. 2002; 3(1):24-32. DOI: 10.1111/j.1520-037x.2000.80355.x. View

10.

Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x. View

11.

Gangwisch J, Heymsfield S, Boden-Albala B, Buijs R, Kreier F, Pickering T . Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006; 47(5):833-9. DOI: 10.1161/01.HYP.0000217362.34748.e0. View

12.

Phillips A, Osborne J . Survey of alternative and nonprescription therapy use. Am J Health Syst Pharm. 2000; 57(14):1361-2. DOI: 10.1093/ajhp/57.14.1361. View

13.

Shoji N, Umeyama A, Saito N, Takemoto T, Kajiwara A, Ohizumi Y . Dehydropipernonaline, an amide possessing coronary vasodilating activity, isolated from Piper longum L. J Pharm Sci. 1986; 75(12):1188-9. DOI: 10.1002/jps.2600751215. View

14.

Johnson M, Pietz K, Battleman D, Beyth R . Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004; 10(12):926-32. View

15.

Bonnet M . Evidence for the pathophysiology of insomnia. Sleep. 2009; 32(4):441-2. PMC: 2663857. DOI: 10.1093/sleep/32.4.441. View

16.

Asgary S, Naderi G, Sarrafzadegan N, Mohammadifard N, Mostafavi S, Vakili R . Antihypertensive and antihyperlipidemic effects of Achillea wilhelmsii. Drugs Exp Clin Res. 2000; 26(3):89-93. View

17.

TSOU K, Brown S, Mackie K, Walker J . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2):393-411. DOI: 10.1016/s0306-4522(97)00436-3. View

18.

Walther S, Mahlberg R, Eichmann U, Kunz D . Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006; 185(4):524-8. DOI: 10.1007/s00213-006-0343-1. View

19.

Schulz K, Altman D, Moher D . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010; 8:18. PMC: 2860339. DOI: 10.1186/1741-7015-8-18. View

20.

Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J . Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-23. DOI: 10.1016/S0140-6736(05)17741-1. View